
Changes at the top for Merck KGaA
pharmafile | September 19, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Belén Garijo, Merck KGaA, Stefan Oschmann
German chemical and pharma giant Merck KGaA has promoted Stefan Oschmann to the position of deputy chief executive and vice chairman.
Also as of January next year another management change occurs when Belén Garijo is appointed to its executive board.
Oschmann (pictured) will share strategic management functions with Karl-Ludwig Kley, who is the firm’s chairman of the executive board. Together they will represent the company with politicians and international organisations.
Garijo is currently the chief executive of Merck’s biopharma division Merck Serono, and will take on responsibility for the whole pharma business which, besides Merck Serono, includes consumer health, allergy and biosimilars.
Johannes Baillou, chairman of the board of partners at Merck says: “Stefan Oschmann who has successfully reorganised our pharma businesses over the past years will familiarise himself with group-wide functions and will increasingly assume external responsibilities for the company.
“Belén Garijo has many years of experience in the pharma industry, has proven that she can further develop our business organisation and in her future role will provide a significant contribution to ensure the sustainable success of our pharma businesses.”
Related Content

Exscientia enters AI drug discovery collaboration with Merck KGaA
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …

Merck KGaA’s cancer drug Bavencio gets EU approval
The EC has approved Merck KGaA’s BAVENCIO (avelumab) as monotherapy for the first-line maintenance treatment …

Company veteran Belén Garijo named as Merck KGaA’s first-ever female CEO
German pharma firm Merck KGaA has taken the decision to appoint its first female Chief …






